Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 163.

https://doi.org/10.1182/blood-2018-163

Published: 2018

Journal Articles

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 1.

https://doi.org/10.1182/blood-2018-99-110805

Published: 2018

Journal Articles

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Blood (2018) 132 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2018-99-111770

Published: 2018

Journal Articles

Physical Activities in Patients with β-Thalassemia As Measured By Fitbit in Association with Patient-Reported Outcomes

Antonis Kattamis, MD, Pranee Sutcharitchan, MD, Ali Taher, MDPhDFRCP, Maria Domenica Cappellini, MD, Dalia Mahmoud, Joseph Pariseau, PharmD, Abderrahmane Laadem, MD, Anzalee Khan, PhD, X. Henry Hu, MD PhD, Vip Viprakasit, MD PhD

Blood (2017) 130 (Supplement 1): 4731.

https://doi.org/10.1182/blood.V130.Suppl_1.4731.4731

Published: 2017

Journal Articles

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Philipp Kiewe, Ulrich Germing, MD, Katharina S. Götze, MD, Karin Mayer, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Joerg Chromik, Dawn Wilson, Xiaosha Zhang, PhD, Chris Rovaldi, MSc, Abderrahmane Laadem, MD, Matthew Leigh Sherman, MD, Kenneth Morris Attie, MD, Joseph Reynolds, PhD, Peter Guest Linde, MD, Aristoteles Giagounidis, MD

Blood (2017) 130 (Supplement 1): 2982.

https://doi.org/10.1182/blood.V130.Suppl_1.2982.2982

Published: 2017

Journal Articles

Quality of Life in Patients with β-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent

Maria Domenica Cappellini, MD, Antonis Kattamis, MD, Vip Viprakasit, MD PhD, Pranee Sutcharitchan, MD, Dalia Mahmoud, Joseph Pariseau, PharmD, Abderrahmane Laadem, MD, Anzalee Khan, PhD, X. Henry Hu, MD PhD, Ali Taher, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 751.

https://doi.org/10.1182/blood.V130.Suppl_1.751.751

Published: 2017

Journal Articles

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

Nianhang Chen, Abderrahmane Laadem, MD, Dawn M. Wilson, Xiaosha Zhang, Matthew L. Sherman, MD, Steve Ritland, Kenneth M. Attie, MD

Blood (2016) 128 (22): 1990.

https://doi.org/10.1182/blood.V128.22.1990.1990

Published: 2016

Journal Articles

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 5551.

https://doi.org/10.1182/blood.V128.22.5551.5551

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Antonio G. Piga, MD, Immacolata Tartaglione, MD, Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, MD, Paolo Ricchi, MD, Vincenzo Caruso, MD, Antonello Pietrangelo, MD, Xiaosha Zhang, Dawn M. Wilson, Ashley Leneus, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2016) 128 (22): 851.

https://doi.org/10.1182/blood.V128.22.851.851

Published: 2016

Journal Articles

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 3168.

https://doi.org/10.1182/blood.V128.22.3168.3168

Published: 2016

Journal Articles

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

Nianhang Chen, Abderrahmane Laadem, MD, Dawn M. Wilson, Xiaosha Zhang, Matthew L. Sherman, MD, Steve Ritland, Kenneth M. Attie, MD

Blood (2016) 128 (22): 2463.

https://doi.org/10.1182/blood.V128.22.2463.2463

Published: 2016

Journal Articles

Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Andrew J. Yee, MD, Jacob P. Laubach, MD, Ajay K. Nooka, MD MPH, Elizabeth K. O'Donnell, MD, Edie A. Weller, PhD, Nicole R. Couture, BSN, RN, Ellen E. Wallace, BA, Jill N. Burke, NP, Cynthia C. Harrington, NP, Marie Puccio-Pick, MS, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4241.

https://doi.org/10.1182/blood.V126.23.4241.4241

Published: 2015

Journal Articles

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Antonio Piga, MD, Silverio Perrotta, MD, M.Rita Gamberini, MD, Ersi Voskaridou, MD, Angela Melpignano, Aldo Filosa, MD, Antonello Pietrangelo, MD, Vincenzo Caruso, MD, Gian Luca Forni, MD, Xiaosha Zhang, Ashley Bellevue, Dawn Wilson, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 752.

https://doi.org/10.1182/blood.V126.23.752.752

Published: 2015

Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 2862.

https://doi.org/10.1182/blood.V126.23.2862.2862

Published: 2015

Journal Articles

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, Lionel Ades, MD PhD, Abderrahmane Laadem, MD, Bond Vo, PharmD, Thomas Prebet, MD PhD, Aspasia Stamatoullas, MD, Thomas Boyd, MD, Jacques Delaunay, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Odile Beyne-Rauzy, MD PhD, Jun Zou, MS, Kenneth Attie, MD, Matthew L. Sherman, MD, Pierre Fenaux, MD PhD, Alan F. List, MD

Blood (2014) 124 (21): 3251.

https://doi.org/10.1182/blood.V124.21.3251.3251

Published: 2014

NARROW

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia

Physical Activities in Patients with β-Thalassemia As Measured By Fitbit in Association with Patient-Reported Outcomes

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

Quality of Life in Patients with β-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only